Baron Health Care Fund: Q3 2026 New Positions And ExitsSeeking Alpha · 7 hr ago
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding FranchiseSeeking Alpha · 5 days ago
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026GlobeNewsWire · 6 days ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 15, 2026
Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)Defense World · Oct 12, 2026
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk VariantsGlobeNewsWire · Oct 6, 2026Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$2.68 | -$1.99 | Beat |
| May 6, 2026 | -$3.61 | -$3.25 | Beat |
| Feb 19, 2026 | $0.04 | -$2.57 | Miss |
| Nov 4, 2025 | -$2.04 | -$5.08 | Miss |
| Aug 5, 2025 | -$3.48 | -$1.90 | Beat |
| May 1, 2025 | -$3.62 | -$3.32 | Beat |